Differences in P-glycoprotein-170 expression and activity between Crohn's disease and ulcerative colitis.

Abstract

The clinical benefit of Cyclosporine A (CsA) in IBD is controversial. Drugs including CsA are substrates of the P-glycoprotein-170 (Pgp-170) cell surface pump. Although the mechanism of action of CsA is complex, we determined that Pgp-170 might be expressed differentially between these two diseases. Intra-epithelial, lamina propria and peripheral blood lymphocytes were stained with the antibody MRK-16, which recognizes the surface antigen Pgp-170. Functional activity was assayed using a Rhodamine dye efflux assay (Rh123). RT-PCR was used to detect Pgp-170 mRNA. Overall, less P-gp-170 surface expression was found on UC CD3+ intestinal lymphocytes compared to controls and Crohn's disease. A decrease in Pgp-170 activity was also measured using the Rh123 functional assay. Fewer CD8+ intraepithelial lymphocytes (IEL) (which intrinsically have more Pgp-170 function) were also found in UC. Furthermore, UC IEL P-gp expression was under the limit of detection by RT-PCR. Overall, greater and differential expression, function and mRNA for Pgp-170 was found in Crohn's disease compared to the UC and normal tissues analyzed.

Statistics

0500'02'04'06'08'10'12'14'16
Citations per Year

1,584 Citations

Semantic Scholar estimates that this publication has 1,584 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Yacyshyn1999DifferencesIP, title={Differences in P-glycoprotein-170 expression and activity between Crohn's disease and ulcerative colitis.}, author={Bruce R. Yacyshyn and Walter P. Maksymowych and Mary Beth Bowen-Yacyshyn}, journal={Human immunology}, year={1999}, volume={60 8}, pages={677-87} }